Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome

A controlled clinical trial

B. Dautzenberg, C. Truffot, S. Legris, M. C. Meyohas, H. C. Berlie, A. Mercat, S. Chevret, J. Grosset

Research output: Contribution to journalArticle

Abstract

Disseminated Mycobacterium avium infection is common in patients with acquired immune deficiency syndrome (AIDS), but no drug studies have been reported establishing antimicrobial activity against this organism in a controlled, randomized trial. Clarithromycin, a new macrolide, has activity against M. avium in vitro and in animals, but it has not been studied in humans. In this randomized, double-blind, placebo-controlled trial, we measured the ability of clarithromycin to reduce M. avium bacteremia in patients with AIDS and disseminated infection. Of 23 patients initially enrolled, 15 men with late-stage AIDS qualified for the study. One group received clarithromycin alone for 6 wk, then placebo plus rifampin, isoniazid, ethambutol, and clofazimine for 6 wk. The other group received placebo alone, then clarithromycin plus the other four drugs. Colony-forming units (CFU) of M. avium per milliliter of blood were determined by quantitative cultures taken at baseline and every 2 wk thereafter. Minimum inhibitory concentration of clarithromycin for 90% of the strains isolated from patients at baseline, as measured on 7H11 agar at pH 6.6, was 8 μg/ml. Eight eligible patients with initial positive cultures who were initially receiving clarithromycin alone had marked declines in blood M. avium CFU; in six cases, CFU decreased to zero. When seven patients were switched to placebo plus the other four drugs, CFU rose in four patients and remained undetectable in three. The five eligible patients initially treated with placebo had progressive CFU increases; when three were switched to clarithromycin plus the four drugs, their CFU declined. We conclude that clarithromycin has consistent activity against M. avium and may benefit patients with AIDS and disseminated M. avium infection.

Original languageEnglish (US)
Pages (from-to)564-569
Number of pages6
JournalAmerican Review of Respiratory Disease
Volume144
Issue number3 I
StatePublished - 1991
Externally publishedYes

Fingerprint

Mycobacterium avium
Mycobacterium Infections
Clarithromycin
Controlled Clinical Trials
Acquired Immunodeficiency Syndrome
Stem Cells
Placebos
Pharmaceutical Preparations
Clofazimine
Ethambutol
Macrolides
Isoniazid
Microbial Sensitivity Tests
Rifampin
Bacteremia
Agar
Randomized Controlled Trials

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Dautzenberg, B., Truffot, C., Legris, S., Meyohas, M. C., Berlie, H. C., Mercat, A., ... Grosset, J. (1991). Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome: A controlled clinical trial. American Review of Respiratory Disease, 144(3 I), 564-569.

Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome : A controlled clinical trial. / Dautzenberg, B.; Truffot, C.; Legris, S.; Meyohas, M. C.; Berlie, H. C.; Mercat, A.; Chevret, S.; Grosset, J.

In: American Review of Respiratory Disease, Vol. 144, No. 3 I, 1991, p. 564-569.

Research output: Contribution to journalArticle

Dautzenberg, B, Truffot, C, Legris, S, Meyohas, MC, Berlie, HC, Mercat, A, Chevret, S & Grosset, J 1991, 'Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome: A controlled clinical trial', American Review of Respiratory Disease, vol. 144, no. 3 I, pp. 564-569.
Dautzenberg, B. ; Truffot, C. ; Legris, S. ; Meyohas, M. C. ; Berlie, H. C. ; Mercat, A. ; Chevret, S. ; Grosset, J. / Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome : A controlled clinical trial. In: American Review of Respiratory Disease. 1991 ; Vol. 144, No. 3 I. pp. 564-569.
@article{c8710af5d26c45a686292ced58de990f,
title = "Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome: A controlled clinical trial",
abstract = "Disseminated Mycobacterium avium infection is common in patients with acquired immune deficiency syndrome (AIDS), but no drug studies have been reported establishing antimicrobial activity against this organism in a controlled, randomized trial. Clarithromycin, a new macrolide, has activity against M. avium in vitro and in animals, but it has not been studied in humans. In this randomized, double-blind, placebo-controlled trial, we measured the ability of clarithromycin to reduce M. avium bacteremia in patients with AIDS and disseminated infection. Of 23 patients initially enrolled, 15 men with late-stage AIDS qualified for the study. One group received clarithromycin alone for 6 wk, then placebo plus rifampin, isoniazid, ethambutol, and clofazimine for 6 wk. The other group received placebo alone, then clarithromycin plus the other four drugs. Colony-forming units (CFU) of M. avium per milliliter of blood were determined by quantitative cultures taken at baseline and every 2 wk thereafter. Minimum inhibitory concentration of clarithromycin for 90{\%} of the strains isolated from patients at baseline, as measured on 7H11 agar at pH 6.6, was 8 μg/ml. Eight eligible patients with initial positive cultures who were initially receiving clarithromycin alone had marked declines in blood M. avium CFU; in six cases, CFU decreased to zero. When seven patients were switched to placebo plus the other four drugs, CFU rose in four patients and remained undetectable in three. The five eligible patients initially treated with placebo had progressive CFU increases; when three were switched to clarithromycin plus the four drugs, their CFU declined. We conclude that clarithromycin has consistent activity against M. avium and may benefit patients with AIDS and disseminated M. avium infection.",
author = "B. Dautzenberg and C. Truffot and S. Legris and Meyohas, {M. C.} and Berlie, {H. C.} and A. Mercat and S. Chevret and J. Grosset",
year = "1991",
language = "English (US)",
volume = "144",
pages = "564--569",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "3 I",

}

TY - JOUR

T1 - Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome

T2 - A controlled clinical trial

AU - Dautzenberg, B.

AU - Truffot, C.

AU - Legris, S.

AU - Meyohas, M. C.

AU - Berlie, H. C.

AU - Mercat, A.

AU - Chevret, S.

AU - Grosset, J.

PY - 1991

Y1 - 1991

N2 - Disseminated Mycobacterium avium infection is common in patients with acquired immune deficiency syndrome (AIDS), but no drug studies have been reported establishing antimicrobial activity against this organism in a controlled, randomized trial. Clarithromycin, a new macrolide, has activity against M. avium in vitro and in animals, but it has not been studied in humans. In this randomized, double-blind, placebo-controlled trial, we measured the ability of clarithromycin to reduce M. avium bacteremia in patients with AIDS and disseminated infection. Of 23 patients initially enrolled, 15 men with late-stage AIDS qualified for the study. One group received clarithromycin alone for 6 wk, then placebo plus rifampin, isoniazid, ethambutol, and clofazimine for 6 wk. The other group received placebo alone, then clarithromycin plus the other four drugs. Colony-forming units (CFU) of M. avium per milliliter of blood were determined by quantitative cultures taken at baseline and every 2 wk thereafter. Minimum inhibitory concentration of clarithromycin for 90% of the strains isolated from patients at baseline, as measured on 7H11 agar at pH 6.6, was 8 μg/ml. Eight eligible patients with initial positive cultures who were initially receiving clarithromycin alone had marked declines in blood M. avium CFU; in six cases, CFU decreased to zero. When seven patients were switched to placebo plus the other four drugs, CFU rose in four patients and remained undetectable in three. The five eligible patients initially treated with placebo had progressive CFU increases; when three were switched to clarithromycin plus the four drugs, their CFU declined. We conclude that clarithromycin has consistent activity against M. avium and may benefit patients with AIDS and disseminated M. avium infection.

AB - Disseminated Mycobacterium avium infection is common in patients with acquired immune deficiency syndrome (AIDS), but no drug studies have been reported establishing antimicrobial activity against this organism in a controlled, randomized trial. Clarithromycin, a new macrolide, has activity against M. avium in vitro and in animals, but it has not been studied in humans. In this randomized, double-blind, placebo-controlled trial, we measured the ability of clarithromycin to reduce M. avium bacteremia in patients with AIDS and disseminated infection. Of 23 patients initially enrolled, 15 men with late-stage AIDS qualified for the study. One group received clarithromycin alone for 6 wk, then placebo plus rifampin, isoniazid, ethambutol, and clofazimine for 6 wk. The other group received placebo alone, then clarithromycin plus the other four drugs. Colony-forming units (CFU) of M. avium per milliliter of blood were determined by quantitative cultures taken at baseline and every 2 wk thereafter. Minimum inhibitory concentration of clarithromycin for 90% of the strains isolated from patients at baseline, as measured on 7H11 agar at pH 6.6, was 8 μg/ml. Eight eligible patients with initial positive cultures who were initially receiving clarithromycin alone had marked declines in blood M. avium CFU; in six cases, CFU decreased to zero. When seven patients were switched to placebo plus the other four drugs, CFU rose in four patients and remained undetectable in three. The five eligible patients initially treated with placebo had progressive CFU increases; when three were switched to clarithromycin plus the four drugs, their CFU declined. We conclude that clarithromycin has consistent activity against M. avium and may benefit patients with AIDS and disseminated M. avium infection.

UR - http://www.scopus.com/inward/record.url?scp=0025948040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025948040&partnerID=8YFLogxK

M3 - Article

VL - 144

SP - 564

EP - 569

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 3 I

ER -